This injectable drug class focuses on the incretin system and leads to increased insulin secretion, decreased glucagon secretion, and slowed gastric emptying. One of its advantages is that its use can lead to weight loss: Answer: 1. GLP-1 receptor agonists Diabetes Care 2011 May; 34(Supplement 2): S279-S284. http://dx.doi.org/10.2337/dc11-s231
CorrectIncorrect